Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09AAK
|
|||
| Drug Name |
Ripretinib
|
|||
| Synonyms |
1442472-39-0; Ripretinib [USAN]; UNII-9XW757O13D; GTPL9175; SCHEMBL14999718; 9XW757O13D; HY-112306; CS-0044835; N-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-N'-phenylurea; 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea; Urea, N-(4-bromo-5-(1-ethyl-1,2-dihydro-7-(methylamino)-2-oxo-1,6-naphthyridin-3-yl)-2-fluorophenyl)-N'-phenyl-
Click to Show/Hide
|
|||
| Indication | Gastrointestinal stromal tumour [ICD-11: 2B5B] | Approved | [1] | |
| Glioma [ICD-11: 2A00.0; ICD-9: 191] | Phase 1 | [2], [3] | ||
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [2] | ||
| Systemic mastocytosis [ICD-11: 2A21.0; ICD-9: 202.6, 757.33] | Phase 1 | [2] | ||
| Company |
Deciphera Pharmaceuticals Waltham, MA
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C24H21BrFN5O2
|
|||
| Canonical SMILES |
CCN1C2=CC(=NC=C2C=C(C1=O)C3=CC(=C(C=C3Br)F)NC(=O)NC4=CC=CC=C4)NC
|
|||
| InChI |
1S/C24H21BrFN5O2/c1-3-31-21-12-22(27-2)28-13-14(21)9-17(23(31)32)16-10-20(19(26)11-18(16)25)30-24(33)29-15-7-5-4-6-8-15/h4-13H,3H2,1-2H3,(H,27,28)(H2,29,30,33)
|
|||
| InChIKey |
CEFJVGZHQAGLHS-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1442472-39-0
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.